MA37963A1 - Protéines de fusion pour traiter un syndrome métabolique - Google Patents
Protéines de fusion pour traiter un syndrome métaboliqueInfo
- Publication number
- MA37963A1 MA37963A1 MA37963A MA37963A MA37963A1 MA 37963 A1 MA37963 A1 MA 37963A1 MA 37963 A MA37963 A MA 37963A MA 37963 A MA37963 A MA 37963A MA 37963 A1 MA37963 A1 MA 37963A1
- Authority
- MA
- Morocco
- Prior art keywords
- treat
- fusion proteins
- metabolic syndrome
- fusion protein
- adiposity
- Prior art date
Links
- 102000037865 fusion proteins Human genes 0.000 title abstract 3
- 108020001507 fusion proteins Proteins 0.000 title abstract 3
- 208000001145 Metabolic Syndrome Diseases 0.000 title 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 title 1
- 208000032928 Dyslipidaemia Diseases 0.000 abstract 1
- 102000003973 Fibroblast growth factor 21 Human genes 0.000 abstract 1
- 108090000376 Fibroblast growth factor 21 Proteins 0.000 abstract 1
- 229940089838 Glucagon-like peptide 1 receptor agonist Drugs 0.000 abstract 1
- 208000017170 Lipid metabolism disease Diseases 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 101710176384 Peptide 1 Proteins 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 230000003328 fibroblastic effect Effects 0.000 abstract 1
- 239000003102 growth factor Substances 0.000 abstract 1
- GNZCSGYHILBXLL-UHFFFAOYSA-N n-tert-butyl-6,7-dichloro-3-methylsulfonylquinoxalin-2-amine Chemical compound ClC1=C(Cl)C=C2N=C(S(C)(=O)=O)C(NC(C)(C)C)=NC2=C1 GNZCSGYHILBXLL-UHFFFAOYSA-N 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1825—Fibroblast growth factor [FGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/50—Fibroblast growth factor [FGF]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/57563—Vasoactive intestinal peptide [VIP]; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/90—Fusion polypeptide containing a motif for post-translational modification
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Endocrinology (AREA)
- Toxicology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Emergency Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Child & Adolescent Psychology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
L'invention concerne une protéine de fusion comprenant au moins un composé fgf-21 (facteur 21 de croissance fibroblastique) et au moins un agoniste de glp-1r (récepteur du peptide 1 de type glucagon), ainsi que des compositions pharmaceutiques, des utilisations médicales et des méthodes de traitement impliquant la protéine de fusion, en particulier dans le domaine du diabète, de la dyslipidémie, de l'obésité et/ou de l'adiposité.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP12306072 | 2012-09-07 | ||
PCT/EP2013/068239 WO2014037373A1 (fr) | 2012-09-07 | 2013-09-04 | Protéines de fusion pour traiter un syndrome métabolique |
Publications (1)
Publication Number | Publication Date |
---|---|
MA37963A1 true MA37963A1 (fr) | 2018-06-29 |
Family
ID=46888349
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA37963A MA37963A1 (fr) | 2012-09-07 | 2013-09-04 | Protéines de fusion pour traiter un syndrome métabolique |
Country Status (25)
Country | Link |
---|---|
US (3) | US20140073563A1 (fr) |
EP (1) | EP2892919A1 (fr) |
JP (1) | JP2015533483A (fr) |
KR (1) | KR20150043505A (fr) |
CN (1) | CN104736558A (fr) |
AR (1) | AR092456A1 (fr) |
AU (1) | AU2013311777B2 (fr) |
BR (1) | BR112015004734A2 (fr) |
CA (1) | CA2880929A1 (fr) |
CL (1) | CL2015000379A1 (fr) |
CR (1) | CR20150149A (fr) |
DO (1) | DOP2015000020A (fr) |
EA (1) | EA201590525A1 (fr) |
GT (1) | GT201500049A (fr) |
HK (1) | HK1207097A1 (fr) |
IL (1) | IL237032A0 (fr) |
MA (1) | MA37963A1 (fr) |
MX (1) | MX2015002985A (fr) |
PE (1) | PE20150648A1 (fr) |
PH (1) | PH12015500194A1 (fr) |
SG (1) | SG11201500682WA (fr) |
TN (1) | TN2015000053A1 (fr) |
TW (1) | TW201414750A (fr) |
UY (1) | UY35018A (fr) |
WO (1) | WO2014037373A1 (fr) |
Families Citing this family (65)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008121563A2 (fr) | 2007-03-30 | 2008-10-09 | Ambrx, Inc. | Polypeptides fgf-21 modifiés, et leurs utilisations |
CN113683705A (zh) | 2011-07-01 | 2021-11-23 | 恩格姆生物制药公司 | 用于代谢病症和疾病治疗的组合物、应用和方法 |
US9290557B2 (en) | 2012-11-28 | 2016-03-22 | Ngm Biopharmaceuticals, Inc. | Compositions comprising variants and fusions of FGF19 polypeptides |
CA2892152A1 (fr) | 2012-11-28 | 2014-06-05 | Ngm Biopharmaceuticals, Inc. | Compositions et methodes de traitement de troubles et maladies metaboliques |
CN108888757A (zh) | 2012-12-27 | 2018-11-27 | 恩格姆生物制药公司 | 用于调节胆汁酸体内稳态及治疗胆汁酸紊乱和疾病的方法 |
US9273107B2 (en) | 2012-12-27 | 2016-03-01 | Ngm Biopharmaceuticals, Inc. | Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases |
CN105828878A (zh) | 2013-10-28 | 2016-08-03 | 恩格姆生物制药公司 | 癌症模型及相关方法 |
SG11201606018UA (en) | 2014-01-24 | 2016-08-30 | Ngm Biopharmaceuticals Inc | Binding proteins and methods of use thereof |
WO2015138278A1 (fr) | 2014-03-11 | 2015-09-17 | Novartis Ag | Méthodes de traitement de troubles métaboliques associés à des lipodystrophies et à des défauts dans la production ou la signalisation de l'insuline |
WO2015183890A2 (fr) | 2014-05-28 | 2015-12-03 | Ngm Biopharmaceuticals, Inc. | Méthodes et compositions pour le traitement de maladies et de troubles métaboliques |
WO2015195509A2 (fr) | 2014-06-16 | 2015-12-23 | Ngm Biopharmaceuticals, Inc. | Procédés et utilisations pour la modulation de l'homéostasie de l'acide biliaire et le traitement de troubles et maladies de l'acide biliaire |
CN110179792A (zh) * | 2014-07-29 | 2019-08-30 | 深圳君圣泰生物技术有限公司 | 小檗碱盐、熊去氧胆酸盐、相关复方及其制备方法和应用 |
US10517929B2 (en) | 2014-10-23 | 2019-12-31 | Ngm Biopharmaceuticals, Inc. | Pharmaceutical compositions comprising FGF19 variants |
MX2017004947A (es) | 2014-10-24 | 2017-06-29 | Bristol Myers Squibb Co | Polipeptidos del factor de crecimiento de fibroblastos 2 (fgf-21) modificados y usos de los mismos. |
WO2016073855A1 (fr) | 2014-11-07 | 2016-05-12 | Ngm Biopharmaceuticals, Inc. | Procédés de traitement de troubles liés à l'acide biliaire et prédiction de la sensibilité clinique au traitement de troubles liés aux acides biliaires |
TWI681966B (zh) * | 2014-12-23 | 2020-01-11 | 丹麥商諾佛 儂迪克股份有限公司 | Fgf21衍生物及其用途 |
CN110204617B (zh) * | 2014-12-31 | 2023-06-16 | 天境生物科技(上海)有限公司 | 含胰高血糖素样肽-1和免疫球蛋白杂合Fc的融合多肽及其用途 |
WO2017019957A2 (fr) | 2015-07-29 | 2017-02-02 | Ngm Biopharmaceuticals, Inc. | Protéines de liaison et leurs procédés d'utilisation |
KR20180033586A (ko) | 2015-08-04 | 2018-04-03 | 듀크 유니버시티 | 전달을 위한 유전적으로 인코딩된 내재적으로 무질서화된 스텔스 중합체 및 이의 이용 방법 |
KR102670157B1 (ko) * | 2015-10-28 | 2024-05-29 | 주식회사유한양행 | 이중 작용 단백질 및 이를 포함하는 약학적 조성물 |
CA3003616C (fr) | 2015-11-09 | 2020-07-28 | Ngm Biopharmaceuticals, Inc. | Methodes de traitement de troubles associes aux acides biliaires |
US11752213B2 (en) | 2015-12-21 | 2023-09-12 | Duke University | Surfaces having reduced non-specific binding and antigenicity |
ES2916998T3 (es) | 2016-01-13 | 2022-07-06 | Novo Nordisk As | Análogos del EGF(A) con sustituyentes de ácidos grasos |
JP2019514908A (ja) * | 2016-04-29 | 2019-06-06 | ディフェンシン セラピューティクス エーピーエス | 肝臓、胆管および膵臓の障害の治療 |
US11467156B2 (en) | 2016-06-01 | 2022-10-11 | Duke University | Nonfouling biosensors |
EP3502143A4 (fr) | 2016-08-19 | 2020-07-15 | Ampsource Biopharma Shanghai Inc. | Peptide de liaison pour la construction d'une protéine de fusion |
CN106317226B (zh) | 2016-08-19 | 2017-09-05 | 安源医药科技(上海)有限公司 | 用于构建融合蛋白的连接肽 |
CN106279437B (zh) | 2016-08-19 | 2017-10-31 | 安源医药科技(上海)有限公司 | 高糖基化人凝血因子viii融合蛋白及其制备方法与用途 |
WO2018039557A1 (fr) | 2016-08-26 | 2018-03-01 | Ngm Biopharmaceuticals, Inc. | Méthodes de traitement de cancers et de tumeurs à médiation assurée par le facteur de croissance des fibroblastes 19 |
RU2019122785A (ru) | 2016-12-22 | 2021-01-22 | Санофи | Комбинации соединения на основе fgf21/агониста glp-1r с оптимизированным соотношением активности |
US11648200B2 (en) | 2017-01-12 | 2023-05-16 | Duke University | Genetically encoded lipid-polypeptide hybrid biomaterials that exhibit temperature triggered hierarchical self-assembly |
CN108440668A (zh) * | 2017-02-16 | 2018-08-24 | 瑞阳(苏州)生物科技有限公司 | Fgf21与igf-1的融合蛋白及其应用 |
US20220127322A1 (en) * | 2017-03-14 | 2022-04-28 | Sunshine Lake Pharma Co., Ltd. | Dual-target fusion proteins comprising the fc portion of an immunoglobulin |
EP3612637A4 (fr) | 2017-04-21 | 2021-01-27 | Yuhan Corporation | Procédé de production de protéines à double fonction et ses dérivés |
US11554097B2 (en) | 2017-05-15 | 2023-01-17 | Duke University | Recombinant production of hybrid lipid-biopolymer materials that self-assemble and encapsulate agents |
US11680083B2 (en) | 2017-06-30 | 2023-06-20 | Duke University | Order and disorder as a design principle for stimuli-responsive biopolymer networks |
PE20200720A1 (es) | 2017-07-19 | 2020-07-21 | Novo Nordisk As | Compuestos bifuncionales |
MX2020002977A (es) | 2017-09-22 | 2020-11-06 | Regeneron Pharma | Agonistas de receptor de peptido similar al glucagon tipo 1 y usos de los mismos. |
ES2923152T3 (es) * | 2017-11-06 | 2022-09-23 | Thena Biotech S R L | Proteínas de fusión basadas en ferritina humana y péptidos escindibles por proteasas y su uso como vehículos quimioterapéuticos |
CN109836504B (zh) * | 2017-11-24 | 2022-08-02 | 浙江道尔生物科技有限公司 | 一种治疗代谢疾病的多结构域活性蛋白 |
WO2019119673A1 (fr) | 2017-12-19 | 2019-06-27 | 北京吉源生物科技有限公司 | Cellule souche modifiée par deux gènes et utilisation de cette dernière |
CN110028587B (zh) * | 2018-01-11 | 2021-10-08 | 安源医药科技(上海)有限公司 | 用于调节血糖和脂质的增效型双功能蛋白 |
AU2019218147B2 (en) * | 2018-02-08 | 2023-06-08 | Sunshine Lake Pharma Co., Ltd. | FGF21 variant, fusion protein and application thereof |
CN112566655A (zh) * | 2018-06-21 | 2021-03-26 | 赛诺菲 | 具有优化的活性比率的fgf21化合物/glp-1r激动剂组合 |
EP3829622A4 (fr) * | 2018-08-02 | 2022-05-11 | Duke University | Protéines de fusion à double agoniste |
CN109836486B (zh) * | 2019-01-30 | 2020-09-08 | 北京双因生物科技有限公司 | 成纤维生长因子21变体、其融合蛋白及其用途 |
CN114853908B (zh) * | 2019-05-16 | 2024-06-07 | 浙江道尔生物科技有限公司 | 一种治疗代谢疾病的融合蛋白 |
US11512314B2 (en) | 2019-07-12 | 2022-11-29 | Duke University | Amphiphilic polynucleotides |
EP4085077A4 (fr) | 2019-12-31 | 2024-01-17 | Beijing QL Biopharmaceutical Co., Ltd. | Protéines de fusion de glp-1 et de gdf15 et leurs conjugués |
WO2021139744A1 (fr) | 2020-01-11 | 2021-07-15 | Beijing Ql Biopharmaceutical Co., Ltd. | Conjugués de protéines de fusion du glp-1 et du fgf21 |
US11981718B2 (en) | 2020-05-27 | 2024-05-14 | Ampsource Biopharma Shanghai Inc. | Dual-function protein for lipid and blood glucose regulation |
CN113735977A (zh) * | 2020-05-28 | 2021-12-03 | 江苏康缘瑞翱生物医药科技有限公司 | rhFGF21融合蛋白、编码其的多核苷酸、包含其组合物及其用途 |
US20220010021A1 (en) | 2020-07-02 | 2022-01-13 | Sanofi | FGFR1/KLB Targeting Agonistic Antigen-Binding Proteins and Conjugates Thereof with GLP-1R Agonistic Peptides |
US20230357346A1 (en) * | 2020-07-10 | 2023-11-09 | Gi Innovation, Inc. | Fusion protein including glucagon-like peptide-1 and interleukin-1 receptor antagonist and use thereof |
WO2022117044A1 (fr) * | 2020-12-03 | 2022-06-09 | Sunshine Lake Pharma Co., Ltd. | Polypeptide agoniste du récepteur double glp-1/gcg et sa protéine de fusion |
AR125086A1 (es) * | 2021-03-23 | 2023-06-07 | Lilly Co Eli | Composiciones que contienen análogos de incretina y usos de estas |
CN113150172B (zh) * | 2021-04-28 | 2023-09-22 | 中国药科大学 | Glp-1r/gipr双靶点激动剂融合蛋白及其制备方法与应用 |
WO2022256568A1 (fr) * | 2021-06-02 | 2022-12-08 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Procédés et compositions pour la localisation de facteurs de croissance |
EP4288461A1 (fr) * | 2021-07-14 | 2023-12-13 | Beijing QL Biopharmaceutical Co., Ltd. | Polypeptides de fusion pour troubles métaboliques |
CN113583142A (zh) * | 2021-08-20 | 2021-11-02 | 赣江中药创新中心 | 双靶点融合蛋白、编码基因、载体或宿主细胞及其应用与表达和纯化方法 |
WO2023049631A2 (fr) * | 2021-09-09 | 2023-03-30 | Northwestern University | Procédés et compositions acellulaires comprenant des hormones thérapeutiques sans marqueur |
US20240199728A1 (en) | 2022-09-21 | 2024-06-20 | Regeneron Pharmaceuticals, Inc. | Methods of treating obesity, diabetes, and liver dysfunction |
WO2024097875A1 (fr) * | 2022-11-02 | 2024-05-10 | Shattuck Labs, Inc. | Protéines de fusion pour le traitement de la stéatohépatite non alcoolique |
CN117801124A (zh) * | 2024-02-29 | 2024-04-02 | 天津凯莱英生物科技有限公司 | 利西那肽前体的融合蛋白及其应用 |
CN117801125B (zh) * | 2024-02-29 | 2024-05-24 | 天津凯莱英生物科技有限公司 | 艾塞那肽前体的融合蛋白及其应用 |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH03219892A (ja) * | 1990-01-24 | 1991-09-27 | Kyowa Hakko Kogyo Co Ltd | タンパク質の製造法 |
GB9725556D0 (en) * | 1997-12-03 | 1998-02-04 | Ciba Geigy Ag | Organic compounds |
KR20020007287A (ko) * | 1999-01-07 | 2002-01-26 | 추후보정 | Fc 융합 단백질로서 항-비만 단백질의 발현 및 이출 |
US7754208B2 (en) * | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
US7138370B2 (en) * | 2001-10-11 | 2006-11-21 | Amgen Inc. | Specific binding agents of human angiopoietin-2 |
CN1480466A (zh) * | 2002-09-03 | 2004-03-10 | �й������ž�����ҽѧ��ѧԺ����ҽ | 一类溶栓抗凝双功能融合蛋白及应用 |
AP2007003869A0 (en) * | 2004-08-03 | 2007-02-28 | Transtech Pharma Inc | Rage fusion proteins and methods of use |
SG176459A1 (en) * | 2005-07-05 | 2011-12-29 | Univ California | Polynucleotides encoding isoprenoid modifying enzymes and methods of use thereof |
US7625564B2 (en) * | 2006-01-27 | 2009-12-01 | Novagen Holding Corporation | Recombinant human EPO-Fc fusion proteins with prolonged half-life and enhanced erythropoietic activity in vivo |
WO2008088422A2 (fr) * | 2006-10-25 | 2008-07-24 | Amgen Inc. | Agents thérapeutiques à base de peptides toxiques |
WO2009020802A2 (fr) * | 2007-08-03 | 2009-02-12 | Eli Lilly And Company | Traitement de l'obésité |
US8933197B2 (en) * | 2007-08-15 | 2015-01-13 | Amunix Operating Inc. | Compositions comprising modified biologically active polypeptides |
WO2010091122A1 (fr) * | 2009-02-03 | 2010-08-12 | Amunix, Inc. | Polypeptides recombinants étendus et compositions les comprenant |
CN101993485B (zh) * | 2009-08-20 | 2013-04-17 | 重庆富进生物医药有限公司 | 促胰岛素分泌肽类似物同源二聚体及其用途 |
WO2011047180A1 (fr) * | 2009-10-14 | 2011-04-21 | Merrimack Pharmaceuticals, Inc. | Agents de liaison bispécifiques qui ciblent la signalisation igf-1r et erbb3, et leurs utilisations |
WO2011084808A2 (fr) * | 2009-12-21 | 2011-07-14 | Amunix Operating Inc. | Compositions de polypeptides bifonctionnels et procédés pour le traitement de maladies métaboliques et cardiovasculaires |
EP2460527A1 (fr) * | 2010-01-21 | 2012-06-06 | Sanofi | Composition pharmaceutique pour le traitement d'un syndrome métabolique |
US9266939B2 (en) * | 2010-12-27 | 2016-02-23 | Alexion Pharmaceuticals, Inc. | Compositions comprising natriuretic peptides and methods of use thereof |
UY34347A (es) * | 2011-09-26 | 2013-04-30 | Novartis Ag | Proteínas de función dual para tratar trastornos metabólicos |
EP2825557B1 (fr) * | 2012-03-16 | 2017-06-28 | The U.S.A. as represented by the Secretary, Department of Health and Human Services | Fc monomère modifié soluble |
-
2013
- 2013-09-04 MX MX2015002985A patent/MX2015002985A/es unknown
- 2013-09-04 EA EA201590525A patent/EA201590525A1/ru unknown
- 2013-09-04 PE PE2015000288A patent/PE20150648A1/es not_active Application Discontinuation
- 2013-09-04 BR BR112015004734A patent/BR112015004734A2/pt not_active IP Right Cessation
- 2013-09-04 CA CA2880929A patent/CA2880929A1/fr not_active Abandoned
- 2013-09-04 KR KR1020157007317A patent/KR20150043505A/ko not_active Application Discontinuation
- 2013-09-04 EP EP13758851.3A patent/EP2892919A1/fr not_active Withdrawn
- 2013-09-04 MA MA37963A patent/MA37963A1/fr unknown
- 2013-09-04 AU AU2013311777A patent/AU2013311777B2/en not_active Ceased
- 2013-09-04 CN CN201380046749.3A patent/CN104736558A/zh active Pending
- 2013-09-04 SG SG11201500682WA patent/SG11201500682WA/en unknown
- 2013-09-04 JP JP2015530371A patent/JP2015533483A/ja active Pending
- 2013-09-04 WO PCT/EP2013/068239 patent/WO2014037373A1/fr active Application Filing
- 2013-09-05 AR ARP130103163A patent/AR092456A1/es unknown
- 2013-09-06 US US14/019,735 patent/US20140073563A1/en not_active Abandoned
- 2013-09-06 TW TW102132110A patent/TW201414750A/zh unknown
- 2013-09-06 UY UY0001035018A patent/UY35018A/es not_active Application Discontinuation
-
2015
- 2015-01-29 PH PH12015500194A patent/PH12015500194A1/en unknown
- 2015-02-01 IL IL237032A patent/IL237032A0/en unknown
- 2015-02-05 DO DO2015000020A patent/DOP2015000020A/es unknown
- 2015-02-17 CL CL2015000379A patent/CL2015000379A1/es unknown
- 2015-02-18 TN TNP2015000053A patent/TN2015000053A1/fr unknown
- 2015-02-27 GT GT201500049A patent/GT201500049A/es unknown
- 2015-03-19 CR CR20150149A patent/CR20150149A/es unknown
- 2015-08-13 HK HK15107811.5A patent/HK1207097A1/xx unknown
- 2015-12-10 US US14/965,841 patent/US20160194371A1/en not_active Abandoned
-
2018
- 2018-07-27 US US16/047,695 patent/US20190085043A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
WO2014037373A1 (fr) | 2014-03-13 |
UY35018A (es) | 2014-03-31 |
US20160194371A1 (en) | 2016-07-07 |
CL2015000379A1 (es) | 2015-06-05 |
PE20150648A1 (es) | 2015-05-25 |
US20140073563A1 (en) | 2014-03-13 |
AU2013311777B2 (en) | 2018-02-01 |
AR092456A1 (es) | 2015-04-22 |
PH12015500194A1 (en) | 2015-04-20 |
MX2015002985A (es) | 2015-06-22 |
CA2880929A1 (fr) | 2014-03-13 |
EP2892919A1 (fr) | 2015-07-15 |
CN104736558A (zh) | 2015-06-24 |
TW201414750A (zh) | 2014-04-16 |
TN2015000053A1 (en) | 2016-06-29 |
DOP2015000020A (es) | 2015-04-15 |
AU2013311777A1 (en) | 2015-03-19 |
IL237032A0 (en) | 2015-03-31 |
KR20150043505A (ko) | 2015-04-22 |
CR20150149A (es) | 2015-05-29 |
BR112015004734A2 (pt) | 2017-11-21 |
EA201590525A1 (ru) | 2015-07-30 |
JP2015533483A (ja) | 2015-11-26 |
HK1207097A1 (en) | 2016-01-22 |
SG11201500682WA (en) | 2015-02-27 |
GT201500049A (es) | 2016-02-15 |
US20190085043A1 (en) | 2019-03-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA37963A1 (fr) | Protéines de fusion pour traiter un syndrome métabolique | |
EA201290964A1 (ru) | Пептидные конъюгаты агонистов рецептора glp-1 и их применение | |
EA201492053A1 (ru) | Белки фактора роста фибробластов 21 | |
MA35458B1 (fr) | Variants du facteur de croissance des fibroblastes 21 | |
EA201491161A1 (ru) | Фторированные модуляторы рецепторов эстрогенов и их применение | |
EA201491644A1 (ru) | Фармацевтические композиции | |
MA46219B1 (fr) | Composés de co-agonistes du glucagon et du glp-1 | |
EA201270815A1 (ru) | Модуляторы рецепторов эстрогена и их применение | |
EA201201047A1 (ru) | Способы и композиции, в которых применяют слитые полипептиды fgf 23 | |
EA201492064A1 (ru) | Варианты фактора роста фибробластов 21 | |
EA201101524A1 (ru) | Способ и композиция для лечения состояния, связанного с хемосенсорным рецептором | |
MA38406A1 (fr) | Virus de la maladie de newcastle et leurs utilisations | |
EA201100062A1 (ru) | Соединения и способы модулирования рецепторов, связанных с белком g | |
EA201100691A1 (ru) | Антагонисты рецепторов лизофосфатидной кислоты | |
EA201101709A1 (ru) | Полициклические антагонисты рецепторов лизофосфатидной кислоты | |
EA201591176A1 (ru) | Композиции и способы с использованием пептидной метки, связывающейся с гиалуронаном | |
EA201491530A1 (ru) | Модуляторы рецепторов эстрогенов и их применение | |
EA033373B1 (ru) | Композиции на водной основе, предварительно наполненный шприц, их применения и способ доставки гипофукозилированного или нефукозилированного антитела против baffr млекопитающему | |
EP2560660A4 (fr) | Thérapies à base de ligands de récepteurs chimiosensibles | |
EA201370081A1 (ru) | Антитела к cd48 и их применение | |
EA201270720A1 (ru) | Модуляторы рецептора андрогенов и их применение | |
MY166045A (en) | Abeta antibody formulation | |
EA201690064A1 (ru) | Антитела к лектин-подобному рецептору 1 окисленных ldl и способы применения | |
EA201291167A1 (ru) | Замещенные гетероциклилбензилпиразолы и их применение | |
EA201490790A1 (ru) | Пептидные конъюгаты агониста рецептора гастрина и глюкагон подобного пептида 1 |